Drugs / FX005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01291914 | Dec 2010 → Jan 2012 | osteoarthritis, knee | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FX005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01291914 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL3545216 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL3545216 ↗ |